[US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading ->
[Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading ->
[DNDi Press Release] Geneva/New Delhi – 22 July 2019 The results of an innovative “infectivity” study conducted by the Drugs for Neglected Diseases initiative (DNDi) and the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known […] Continue reading ->
Against the background of increased cross-border infection risks, the World Health Organization on Wednesday declared the Ebola virus outbreak in the Democratic Republic of the Congo to be a Public Health Emergency of International Concern (PHEIC) – a decision that may help increase aid flows to the disease epicentre but also threaten free-wheeling patterns of […] Continue reading ->
An estimated 820 million people went hungry in 2018, the third continuous year in a worldwide trend of rising hunger. And over one-quarter of the world’s population, or 2 billion people in all, experienced moderate or severe food insecurity, according to the The State of Food Security and Nutrition in the World report for 2019. […] Continue reading ->